Abstract GS3-02: GS3-02 Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 trial
Mafalda Oliveira, Denys Pominchuck, Zbigniew Nowecki, Erika Hamilton, Yaroslav Kulyaba, Timur Andabekov, Yevhen Hotko, Tamar Melkadze, Gia Nemsadze, Patrick Neven, Yuriy Semegen, Vladmir Vladmirov, Claudio Zamagni, Hannelore Denys, Frédéric Forget, Zsolt Horváth, Alfiya Nesterova, Maxine Bennett, Bistra Kirova, Teresa Klinowska, Justin P.O. Lindemann, Delphine Lissa, Alastair Mathewson, Christopher J. Morrow, Zuzana Traugottova, R. van Zyl, Ekaterine Arkania
Cancer Research, 2023
Abstract
This research paper explore the methodology and findings associated with Cancer Research. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).